• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by IsoPlexis Corporation (Amendment)

    2/1/23 9:26:13 AM ET
    $ISO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $ISO alert in real time by email
    SC 13G/A 1 n2927_sc13ga-x2.htm SC 13G

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

    SCHEDULE 13G

     

    (Amendment No. 1)*

     

     

    Under the Securities Exchange Act of 1934

     

     

    IsoPlexis Corporation
    (Name of Issuer)
     
    Common Stock, par value $0.001 per share
    (Title of Class of Securities)

     

    465005 10 6
    (CUSIP Number)

     

     December 31, 2022
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨ Rule 13d-l(b)

     

    ¨Rule 13d-l(c)

     

    xRule 13d-l(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     
     

     

     

    CUSIP No. 465005 10 6  
       

     

    1.    Names of Reporting Persons

     

    Connecticut Innovations, Incorporated

     
     
    2.    Check the Appropriate Box if a Member of a Group (See Instructions)
       
    ¨   (a)  
    ¨   (b)  
       
       
    3.    SEC Use Only  
       
     
    4.    Citizenship or Place of Organization     Connecticut
           

     

    Number of

    Shares

    Beneficially

    Owned by Each

    Reporting

    Person With:

    5.    Sole Voting Power     2,731,449
       
      6.    Shared Voting Power     0
       
      7.    Sole Dispositive Power   2,731,449
       
      8.    Shared Dispositive Power     0

     

       
    9.    Aggregate Amount Beneficially Owned by Each Reporting Person  2,731,449  
     
    10.  Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions).         ¨
     
    11.  Percent of Class Represented by Amount in Row (9)         6.9%
     
     
    12.  Type of Reporting Person (See Instructions)        CO
     
         

     

     

     

    Page 2 of 5 Pages

     

     

     
     

     

     

    Item 1.

     

    (a) Name of Issuer

     

    IsoPlexis Corporation

     

    (b)  Address of Issuer's Principal Executive Offices

     

    35 NE Industrial Road

    Branford, CT 06405

     

    Item 2.

     

    (a)  Name of Person Filing (the “Reporting Person”)

     

    Connecticut Innovations, Incorporated

     

     (b)  Address of Principal Business Office or, if none, Residence

     

    The Principal Business Office for Connecticut Innovations, Incorporated. is:

     

    470 James Street, Suite 8, New Haven, CT 06513

     

    (c)  Citizenship

     

    The Reporting Person is a Connecticut corporation.

     

    (d)  Title of Class of Securities 

    Common Stock, par value $0.001 per share

    (e)  CUSIP Number 

    465005 10 6

    Item 3. If this statement is filed pursuant to §§240.13d-l(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)        ¨         Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o); 

    (b)        ¨         Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c); 

    (c)        ¨         Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c); 

    (d)        ¨         Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8); 

    (e)        ¨         An investment adviser in accordance with §240.13d-l(b)(l)(ii)(E); 

    (f)        ¨         An employee benefit plan or endowment fund in accordance with §240.13d-l(b)(l)(ii)(F); 

    (g)       ¨         A parent holding company or control person in accordance with § 240.13d-l(b)(l)(ii)(G); 

    (h)       ¨         A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); 

    (i)        ¨         A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); 

    (j)        ¨          A non-U.S. institution in accordance with §240.13d-l(b)(l)(ii)(J). 

    (k)       ¨          Group, in accordance with §240.13d-l(b)(l)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-l(b)(l)(ii)(J), please specify the type of institution: ______________.

     

    Page 3 of 5 Pages

     

     

     

     

     
     

     

     

    Item 4. Ownership.

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    (a)Amount beneficially owned:  2,731,449 shares of Common Stock, par value $0.001 per share

     

     

    (b) Percent of class: 6.9%

     

    The information with respect to percentage ownership is based on a total of 39,575,989 shares of Common Stock, par value $0.001 per share of IsoPlexis Corporation outstanding as of November 8, 2022, as reported in the Issuer's Form 10-Q filed with the Securities and Exchange Commission on November 10, 2022.

     

    (c)

     

    The information required by Item 4(c) is set forth in Rows 5-11 of the cover page hereto for the Reporting Person and is incorporated herein by reference.

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting persons have ceased to be the beneficial owners of more than 5 percent of the class of securities, check the following [ ].

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10. Certifications

     

     Not applicable.

    Page 4 of 5 Pages

     

     

     

     

     
     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

     

    Dated: February 1, 2023  Connecticut Innovations, Incorporated
       
       
       
       By:   /s/ Philip Siuta
        Name:   Philip Siuta
        Title: Chief Operating Officer and Chief Financial Officer
           

      

     

      

    Page 5 of 5 Pages

     

     

     

     

    Get the next $ISO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ISO

    DatePrice TargetRatingAnalyst
    2/15/2022$17.00 → $12.00Overweight
    Morgan Stanley
    1/27/2022$20.00 → $15.00Outperform
    SVB Leerink
    11/19/2021$24.00Outperform
    Evercore ISI Group
    11/11/2021$17.00 → $20.00Outperform
    SVB Leerink
    11/2/2021$17.00Outperform
    SVB Leerink
    11/2/2021Outperform
    Cowen & Co.
    11/2/2021$16.00Overweight
    Morgan Stanley
    More analyst ratings

    $ISO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by IsoPlexis Corporation (Amendment)

      SC 13D/A - IsoPlexis Corp (0001615055) (Subject)

      6/15/23 4:15:39 PM ET
      $ISO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by IsoPlexis Corporation (Amendment)

      SC 13G/A - IsoPlexis Corp (0001615055) (Subject)

      2/14/23 4:33:58 PM ET
      $ISO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by IsoPlexis Corporation (Amendment)

      SC 13G/A - IsoPlexis Corp (0001615055) (Subject)

      2/14/23 2:40:05 PM ET
      $ISO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ISO
    Leadership Updates

    Live Leadership Updates

    See more
    • IsoPlexis Appoints Key Financial and Legal Hires from Leading Tools and Omics Companies

      BRANFORD, Conn., Nov. 30, 2021 /PRNewswire/ -- IsoPlexis (NASDAQ: ISO), the leader in functional single-cell proteomics, today announced the appointment of Richard Rew as Senior VP, General Counsel and Secretary; Raj Khakhar as VP of Finance; and Manny Resendes as Global Controller. These three new appointments further strengthen Isoplexis' financial and legal teams. "We are excited to have Mr. Rew, Mr. Khakhar, and Mr. Resendes join our team at IsoPlexis," said Sean Mackay, CEO of IsoPlexis. "These recent hires will strengthen our ability to accelerate our growth trajectory a

      11/30/21 7:00:00 AM ET
      $ISO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • IsoPlexis Bolsters Its Global Operational and Product Support Leadership

      BRANFORD, Conn., Nov. 12, 2021 /PRNewswire/ -- IsoPlexis (NASDAQ:ISO), the leader in functional single-cell proteomics, today announced the appointment of two new leadership positions at the company. Michelle Reid, Ph.D. joins IsoPlexis as VP of Service and Support, and Anthony Catalano joins as the Senior VP of Operations. With these appointments, IsoPlexis continues to strengthen its operations and product support teams, providing high need proteomic products with highly customer centric support. Ms. Reid comes to IsoPlexis with over 20 years of experience leading and devel

      11/12/21 7:00:00 AM ET
      $ISO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • IsoPlexis Bolsters Its Global Operational and Product Support Leadership

      BRANFORD, Conn., Nov. 12, 2021 /PRNewswire/ -- IsoPlexis (NASDAQ:ISO), the leader in functional single-cell proteomics, today announced the appointment of two new leadership positions at the company. Michelle Reid, Ph.D. joins IsoPlexis as VP of Service and Support, and Anthony Catalano joins as the Senior VP of Operations. With these appointments, IsoPlexis continues to strengthen its operations and product support teams, providing high need proteomic products with highly customer centric support. Ms. Reid comes to IsoPlexis with over 20 years of experience leading and devel

      11/12/21 7:00:00 AM ET
      $ISO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ISO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Morgan Stanley reiterated coverage on IsoPlexis with a new price target

      Morgan Stanley reiterated coverage of IsoPlexis with a rating of Overweight and set a new price target of $12.00 from $17.00 previously

      2/15/22 10:15:01 AM ET
      $ISO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SVB Leerink reiterated coverage on IsoPlexis with a new price target

      SVB Leerink reiterated coverage of IsoPlexis with a rating of Outperform and set a new price target of $15.00 from $20.00 previously

      1/27/22 4:33:30 AM ET
      $ISO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Evercore ISI Group initiated coverage on IsoPlexis with a new price target

      Evercore ISI Group initiated coverage of IsoPlexis with a rating of Outperform and set a new price target of $24.00

      11/19/21 7:09:33 AM ET
      $ISO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ISO
    Financials

    Live finance-specific insights

    See more
    • Berkeley Lights to Acquire IsoPlexis, Creating a Premier Functional Cell Biology Company

      Complementary Technologies, Customer Bases, and Commercial Channels to Strengthen Leadership in High-Growth, Single-Cell Biology Significant Cost Synergies to Increase Profitability and Accelerate Breakeven Horizon in 2024, Earlier Than Berkeley Lights Expected as a Standalone Entity Companies to Host Joint Conference Call and Webcast Today at 5:00 p.m. ET EMERYVILLE, CA and BRANFORD, Conn., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Berkeley Lights (NASDAQ:BLI), a life sciences tools company, and IsoPlexis (NASDAQ:ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced a definitive agreement under which Berkeley Lights will acquire

      12/21/22 4:49:03 PM ET
      $BLI
      $ISO
      Medicinal Chemicals and Botanical Products
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
    • Berkeley Lights to Acquire IsoPlexis, Creating a Premier Functional Cell Biology Company

      Complementary Technologies, Customer Bases, and Commercial Channels to Strengthen Leadership in High-Growth, Single-Cell Biology Significant Cost Synergies to Increase Profitability and Accelerate Breakeven Horizon in 2024, Earlier Than Berkeley Lights Expected as a Standalone Entity Companies to Host Joint Conference Call and Webcast Today at 5:00 p.m. ET EMERYVILLE, Calif. and BRANFORD, Conn., Dec. 21, 2022 /PRNewswire/ -- Berkeley Lights (NASDAQ:BLI), a life sciences tools company, and IsoPlexis (NASDAQ:ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced a definitive agreement under which Berkeley Lights will acquire IsoP

      12/21/22 4:15:00 PM ET
      $BLI
      $ISO
      Medicinal Chemicals and Botanical Products
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
    • IsoPlexis to Report Third Quarter 2022 Financial Results on November 10, 2022

      BRANFORD, Conn., Oct. 19, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (NASDAQ:ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced it will report financial results for the third quarter 2022 before market open on Thursday, November 10, 2022. Company management will be webcasting a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.isoplexis.com. The webcast will be archived and available for replay after the event. About IsoPlexis IsoPlexis is empowering labs to leverage the ce

      10/19/22 7:00:00 AM ET
      $ISO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ISO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Khakhar Rajesh T.

      4 - IsoPlexis Corp (0001615055) (Issuer)

      3/21/23 5:04:56 PM ET
      $ISO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by Myers Jason W.

      4 - IsoPlexis Corp (0001615055) (Issuer)

      3/21/23 4:53:55 PM ET
      $ISO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by Ho Gregory P.

      4 - IsoPlexis Corp (0001615055) (Issuer)

      3/21/23 4:52:06 PM ET
      $ISO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ISO
    SEC Filings

    See more
    • SEC Form 15-12G filed by IsoPlexis Corporation

      15-12G - IsoPlexis Corp (0001615055) (Filer)

      3/31/23 8:32:18 AM ET
      $ISO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • IsoPlexis Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Leadership Update, Financial Statements and Exhibits

      8-K - IsoPlexis Corp (0001615055) (Filer)

      3/22/23 8:13:01 AM ET
      $ISO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form S-8 POS filed by IsoPlexis Corporation

      S-8 POS - IsoPlexis Corp (0001615055) (Filer)

      3/21/23 5:20:43 PM ET
      $ISO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ISO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Berkeley Lights Completes Acquisition of IsoPlexis Forming PhenomeX, the Functional Cell Biology Company

      PhenomeX to begin trading under symbol (NASDAQ:CELL) EMERYVILLE, Calif., March 21, 2023 /PRNewswire/ -- Berkeley Lights, Inc. (NASDAQ:BLI), a life sciences tools company, today announced that it has completed its previously announced acquisition of IsoPlexis Corporation (NASDAQ:ISO), a company empowering labs to leverage the cells and proteome changing the course of human health. The newly combined company has been renamed PhenomeX and its common stock will begin trading on Nasdaq under the ticker symbol "CELL" at market open tomorrow. PhenomeX is positioned to be the leading

      3/21/23 8:02:00 AM ET
      $BLI
      $ISO
      Medicinal Chemicals and Botanical Products
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
    • IsoPlexis Reports Preliminary Full Year 2022 Revenue

      BRANFORD, Conn., Jan. 12, 2023 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (NASDAQ: ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced its preliminary unaudited revenue for the full year ended December 31, 2022. Total revenue for the full year ended December 31, 2022 is expected to be in the range of $16.6 to $16.8 million, representing a decrease of approximately 3% to 4% compared to $17.3 million for the full year ended December 31, 2021. Fourth quarter results were lower than expected primarily due to the timing of customer orders for instruments and lower consumable sales, as the previously described macroeconomic head

      1/12/23 4:05:00 PM ET
      $ISO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Berkeley Lights to Acquire IsoPlexis, Creating a Premier Functional Cell Biology Company

      Complementary Technologies, Customer Bases, and Commercial Channels to Strengthen Leadership in High-Growth, Single-Cell Biology Significant Cost Synergies to Increase Profitability and Accelerate Breakeven Horizon in 2024, Earlier Than Berkeley Lights Expected as a Standalone Entity Companies to Host Joint Conference Call and Webcast Today at 5:00 p.m. ET EMERYVILLE, CA and BRANFORD, Conn., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Berkeley Lights (NASDAQ:BLI), a life sciences tools company, and IsoPlexis (NASDAQ:ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced a definitive agreement under which Berkeley Lights will acquire

      12/21/22 4:49:03 PM ET
      $BLI
      $ISO
      Medicinal Chemicals and Botanical Products
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus